Compounds > 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine
Page last updated: 2024-09-03

4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine and tryptophan

4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine has been researched along with tryptophan in 1 studies

Compound Research Comparison

Studies
(4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine)		Trials
(4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine)		Recent Studies (post-2010)
(4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine)		Studies
(tryptophan)		Trials
(tryptophan)		Recent Studies (post-2010) (tryptophan)
420932,7629367,183

Protein Interaction Comparison

ProteinTaxonomy4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine (IC50)tryptophan (IC50)
MyeloperoxidaseHomo sapiens (human)2.25

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1

Other Studies

1 other study(ies) available for 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine and tryptophan

ArticleYear
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009